Untreated ADHD nearly doubles your car-accident odds

Bottom line

A new meta-analysis pools four adult-driver studies and finds that people with untreated ADHD are nearly twice as likely to be in a motor-vehicle accident as the general driving population. For ADHD readers who drive untreated, this puts the risk in the same band as driving with cannabis or significant sleep deprivation. The practical lever: stimulant medication on driving days reduces it measurably.

The research

Childress and colleagues pooled four studies measuring crash risk in adult drivers with untreated ADHD vs the general driving population. Headline pooled odds ratio: 93% increase (significant pooled OR, p<0.001). The paper’s comparison frame puts that risk against established well-publicised hazards — cannabis 85% higher odds, opioids or benzodiazepines 53%, sleep deprivation 162%. ADHD sits squarely in that band. Older independent studies on stimulant-treated ADHD drivers consistently show measurable risk reduction on days medication is active.

Important context on this specific paper: two of three authors are Tris Pharma employees, and the senior author discloses consulting and research funding from many stimulant manufacturers. The pooled finding is consistent with prior independent estimates from non-industry research; the funding tilts how the paper frames the conclusion (the call-to-action is “treat your ADHD”) but doesn’t invalidate the underlying odds ratios.

What this means

If you have ADHD and drive untreated, the meta puts your accident risk in the same band as driving high or driving exhausted. The case for stimulant medication on days you drive — especially highway driving, night driving, or long trips — is concrete and quantified, not theoretical. This is a real argument for not skipping medication on days you’ll be behind the wheel for extended periods.

For readers not yet diagnosed: driving difficulty is one of the impairment domains DSM-5 explicitly recognises — bring specific examples (near-misses, lane drift, missed exits, attention lapses at intersections) to an assessment. For readers already diagnosed and weighing the medication decision, the question is more about formulation timing than whether — most adult stimulants run 8–12 hours, which covers a workday but not always an evening commute.

Read next on this site:

• Getting diagnosed as an adult — if driving difficulty is one of the patterns that pushed you to consider assessment, this walkthrough covers what a defensible evaluation contains and what to bring.
• Adult ADHD medication walkthrough — duration profiles, the late-afternoon attenuation problem, and why the timing of the dose matters for driving.
• Vyvanse vs Adderall — duration is the dimension that matters most for the driving question. The two have different attenuation curves.